Impact of Novartis’ rebate trial result in pharma industry

While the amendments to the Pharmaceutical Affairs Law and Medical Device Law to tighten punishment for pharmaceutical and medical device companies providing illegal rebates passed the National Assembly plenary session on the 17^th, the final result of the Novartis’ rebate trial is expected to become the eye of a typhoon that will hit the pharmaceutical industry at the end of the year.

This is ...